Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sangamo Therapeutics Inc

SGMO ✗ NOT COMPLIANT ☆ Track — members

OTC Markets · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.18

▲ +6.06%

Market Cap $72.50M · Vol 6.48M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$72.50M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

100.00

Momentum

Beta

1.74

vs Market

52W High

$0.77

77.15% below

52W Low

$0.03

483.33% above

Volume

6.48M

Avg 3.46M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

99.07%

Public shares

Shariah Compliance8 STANDARDS

✗ Sangamo Therapeutics Inc (SGMO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SGMO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+56.25%

+130.26%

+29.15%

-54.77%

YTD

-58.33%

-67.59%

-82.67%

-98.26%

Financials & Valuation

TTM · Annual

Total Revenue	$39.55M
Net Income	$-122,932,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-153.05% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	414.29M

Technical Indicators

50-Day SMA	$0.10
200-Day SMA	$0.30
RSI (14)	100.00
Beta	1.74
52-Week High	$0.77
52-Week Low	$0.03

Volume Today	6.48M
Avg Daily Volume (30D)	3.46M
Relative Volume	1.87x
Volatility (10D)	92.39
Volatility (30D)	178.41
Free Float	99.07%

Analyst Consensus

BUY

Current Price $0.18

Mean Target N/A

52W Low$0.03 52W High$0.77

Current

Target

$0.03 $0.77

Current Analyst target

· 0 analysts

Identifiers

ExchangeOTC Markets

FIGIBBG001S95JZ2

ISINUS8006771062

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 6, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.